BioSpace News Archive

Equillium, Inc. today announced that it has initiated a Phase 2 open-label study of EQ101 to assess efficacy and safety in adult subjects with moderate to severe alopecia areata.

Global molecular diagnostics innovator Sense Biodetection (Sense) today announced it has entered into a strategic agreement with Bio Nuclear Diagnostics, Inc. (BND) for the non-exclusive distribution in Canada of Sense’s Veros instrument-free, point-of-care molecular testing platform.

SQI Diagnostics Inc. (“SQI” or the “Company”) (TSX-V: SQD) (OTCQB: SQIDF) today announced that it has entered into a funding agreement (the “Contribution Agreement”) with the Federal Economic Development Agency for Southern Ontario (“FedDev Ontario”) to support the Company’s manufacturing scale-up and commercialization of its pipeline of products in development, including the Company’s recently approved RALI-DX IL-6 test.

AbCellera (Nasdaq: ABCL) today announced the release of new data on its T-cell engager (TCE) platform at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8 to 12, 2022.

Aimmune Therapeutics to Present Positive Results from Phase 3 POSEIDON Study of PALFORZIA ® [Peanut ( Arachis hypogaea ) Allergen Powder-dnfp] in Peanut-Allergic Children Aged 1 to 3 Years.

Waters Corporation released its 2022 Environmental, Social, and Governance Report highlighting the company’s efforts for 2021 and the first half of 2022 to reduce its environmental footprint, develop a workforce that is more representative of the society we live in, and continue strong governance practices.

Yield10 Bioscience, Inc. announced that the Company has begun its winter 2022/2023 field test and seed production program for Camelina at sites in the United States, Canada, Argentina and Chile.

Milestone Scientific Inc. today announced that it will host a conference call at 8:30 AM Eastern Time on Tuesday, November 15, 2022, to discuss the company’s financial results for the third quarter ended September 30, 2022, as well as the company’s corporate progress and other developments.

Salarius Pharmaceuticals, Inc. today reported financial results for the three and nine months ended September 30, 2022 and provided a business update.

SELLAS Life Sciences Group, Inc. today announced confirmatory top-line clinical data from the final analysis of results from its Phase 1/2 clinical trial of galinpepimut-S (GPS) in combination with Merck’s anti-PD-1 therapy, pembrolizumab (KEYTRUDA®), in patients diagnosed with WT1(+) relapsed or refractory platinum-resistant advanced metastatic ovarian cancer.